• Prescribing Information
  • Formularios En Español
  • Information for Patients
  • FIRAZYR Start Form
    • Enroll Online
    • Fax Form
  • Other Treatment Options
  • Important Safety Information
  • Prescribing Information
FIRAZYR® (icatibant injection) logo.
FIRAZYR® (icatibant injection) logo.
  • Understanding HAE
    • HAE Overview
    • Diagnosis
    • Attack Presentation
    • Unpredictability of Attacks
    • Evolving Treatment Paradigms
  • What is FIRAZYR?
    • Role of Acute Therapy
    • Efficacy
      • Cutaneous & Abdominal Attacks
      • Multiple Attacks & Laryngeal Attacks
    • Dosing & Administration
    • Bradykinin and The FIRAZYR MOA
    • FIRAZYR Safety Profile
  • OnePath® Product Support
    • OnePath® Access & Support
    • Co-Pay Assistance Program
  • Resources
    • Downloadable Materials
    • Useful Links
    • FIRAZYR Sample
    • Takeda's Commitment to FIRAZYR
  • Sign Up
  • Understanding HAE
    • Understanding HAE Overview
    • HAE Overview
    • Diagnosis
    • Attack Presentation
    • Unpredictability of Attacks
    • Evolving Treatment Paradigms
  • What is FIRAZYR?
    • What is FIRAZYR? Overview
    • Role of Acute Therapy
    • Efficacy
      • Cutaneous & Abdominal Attacks
      • Multiple Attacks & Laryngeal Attacks
    • Dosing & Administration
    • Bradykinin and The FIRAZYR MOA
    • FIRAZYR Safety Profile
  • OnePath® Product Support
    • OnePath® Product Support Overview
    • OnePath® Access & Support
    • Co-Pay Assistance Program
  • Resources
    • Resources Overview
    • Downloadable Materials
    • Useful Links
    • FIRAZYR Sample
    • Takeda's Commitment to FIRAZYR
  • Sign Up

Other Treatment Options

  • TAKHZYRO®(lanadelumab-flyo) injection
  • Firazyr®(icatibant injection)
  • cinryze®(C1 esterase inhibitor [human])
FIRAZYR® (icatibant injection) logo.
  • Understanding HAE
    • HAE Overview
    • Diagnosis
    • Attack Presentation
    • Unpredictability of Attacks
    • Evolving Treatment Paradigms
  • What is FIRAZYR?
    • Role of Acute Therapy
    • Efficacy
      • Cutaneous & Abdominal Attacks
      • Multiple Attacks & Laryngeal Attacks
    • Dosing & Administration
    • Bradykinin and The FIRAZYR MOA
    • FIRAZYR Safety Profile
  • OnePath® Product Support
    • OnePath® Access & Support
    • Co-Pay Assistance Program
  • Resources
    • Downloadable Materials
    • Useful Links
    • FIRAZYR Sample
    • Takeda's Commitment to FIRAZYR
  • Sign Up
  • Understanding HAE
    • Understanding HAE Overview
    • HAE Overview
    • Diagnosis
    • Attack Presentation
    • Unpredictability of Attacks
    • Evolving Treatment Paradigms
  • What is FIRAZYR?
    • What is FIRAZYR? Overview
    • Role of Acute Therapy
    • Efficacy
      • Cutaneous & Abdominal Attacks
      • Multiple Attacks & Laryngeal Attacks
    • Dosing & Administration
    • Bradykinin and The FIRAZYR MOA
    • FIRAZYR Safety Profile
  • OnePath® Product Support
    • OnePath® Product Support Overview
    • OnePath® Access & Support
    • Co-Pay Assistance Program
  • Resources
    • Resources Overview
    • Downloadable Materials
    • Useful Links
    • FIRAZYR Sample
    • Takeda's Commitment to FIRAZYR
  • Sign Up
  • Formularios en Español
  • Information for Patients
  • FIRAZYR Start Form
    • Enroll Online
    • Fax Form
  • Other Treatment Options
    • Main Menu
    • Other Treatment Options
    • TAKHZYRO®(lanadelumab-flyo) injection
    • Firazyr®(icatibant injection)
    • cinryze®(C1 esterase inhibitor [human])

Site Map

  • Home
  • Understanding HAE
    • HAE Overview
    • Diagnosis
    • Attack Presentation
    • Unpredictability of Attacks
    • Evolving Treatment Paradigms
  • What is FIRAZYR?
    • Role of Acute Therapy
    • Efficacy
      • Cutaneous & Abdominal Attacks
      • Multiple Attacks & Laryngeal Attacks
    • Dosing & Administration
    • Bradykinin and the FIRAZYR MOA
    • FIRAZYR Safety Profile
  • OnePath® Product Support
    • OnePath® Access & Support
    • Co-Pay Assistance Program
  • Resources
    • Downloadable Materials
    • Useful Links
    • FIRAZYR Sample
    • Takeda's Commitment to FIRAZYR
  • Sign Up

Important Safety Information + Expand× Close

Important Safety Information +Important Safety Information ×Important Safety Information

Warnings and precautions: Given the potential for airway obstruction during acute laryngeal HAE attacks, patients should be advised to seek medical attention in an appropriate healthcare facility immediately in addition to treatment with FIRAZYR.

Adverse reactions: The most commonly reported adverse reactions were injection-site reactions, which occurred in almost all patients (97%) in clinical trials. These injection-site reactions included bruising, hematoma, burning, erythema, hypoesthesia, irritation, numbness, edema, pain, pressure sensation, pruritus, swelling, urticaria, and warmth.

Other common adverse reactions included pyrexia (4%), transaminase increase (4%), and dizziness (3%), as well as rash, nausea, and headache.

Drug interactions: FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. Clinical trials to date have excluded subjects taking ACE inhibitors.

Use in specific populations:

Clinical studies of FIRAZYR included a limited number of subjects aged 65 and over. Elderly patients are likely to have increased systemic exposure. Reported clinical experience has not identified differences in efficacy and safety between elderly and younger patients.

Safety and effectiveness in patients below 18 years of age have not been established.

Please see the full Prescribing Information.

To report suspected adverse events, please contact Takeda at 1-800-828-2088 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Indication + Expand× Close

Indication +Indication ×

Indication

FIRAZYR® (icatibant injection) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Takeda logo.
  • For US Audiences
  • Takeda
  • Privacy Notice
  • Legal Notice
  • Contact Us
  • Site Map

This site is intended for US residents and governed by US laws and government regulations. Please see our online Privacy Policy for more information. ©2024 Takeda Pharmaceuticals U.S.A., Inc., 300 Shire Way, Lexington, MA 02421. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA® and the TAKEDA Logo® are registered trademarks of Takeda Pharmaceutical Company Limited. FIRAZYR® and the FIRAZYR Logo® are registered trademarks of Shire Orphan Therapies GmbH. ONEPATH® and the ONEPATH Logo® are registered trademarks of Shire Human Genetic Therapies, Inc.



Are You a Healthcare Professional?

The information in this section of FIRAZYR.com is intended for US healthcare professionals only.

No Yes »